Volume loss

In the single-blind randomized controlled registration trial of Juvederm Voluma XC for age-related midface volume loss (235 treated patients), 85.6 percent improved at least 1 point on a validated volume deficit scale at 6 months, and correction was maintained up to 2 years in a subset. Patient-reported outcomes tracked the clinician ratings: 79 percent still rated their cheeks improved at 2 years. Cheek augmentation is an on-label FDA-approved use for several HA products.

A 2025 systematic review of 20 clinical studies found PLLA effective and well tolerated for facial volumization and collagen stimulation, with high patient satisfaction and results commonly lasting about 2 years. The deepest data comes from HIV-related facial lipoatrophy, where four prospective studies (VEGA, Chelsea and Westminster, APEX002, Blue Pacific, totaling 278 patients) showed significant, durable increases in dermal thickness sustained at least 18 months. FDA approved for HIV facial lipoatrophy (2004), facial wrinkles and folds (2009), and cheek volume.

For volume loss on the backs of the hands, a 12-month multicenter randomized blinded trial in 114 subjects found 75 percent achieved at least a 1-point improvement on the validated Merz Hand Grading Scale at 3 months, generally maintained through 12 months. CaHA is the only filler FDA approved for dorsal hand augmentation. On the face, its high lift capacity makes it a standard choice for cheeks and jawline contouring.